Live Biotherapeutics Drug Discovery Services for Cancer

Gut microbiota is widely considered to be one of the most important components to maintain balanced homeostasis. Looking forward, probiotics have been shown to play a significant role in immunomodulation and display anticancer properties. Clinical studies have shown that some probiotics can reduce the incidence of postoperative inflammation in cancer patients. Equipped with world-leading technology platforms and professional scientific staff in live biotherapeutics drug discovery, Creative Biolabs is committed to providing overall solutions for next-generation probiotics (NGPs) discovery, bioprocess development, and good manufacturing practice (GMP) scale-up. We are dedicated to serving every unique need of our clients in NGP projects.

Summary of the possible applications of probiotic bacteria in the treatment and prevention of cancer. Fig.1 Summary of the possible applications of probiotic bacteria in the treatment and prevention of cancer. (Górska, 2019)

Probiotics in Cancer Therapy

The human intestinal microbiota plays an important role in the development of the gut immune system, metabolism, nutrition absorption, resistance to pathogenic microorganisms, and modulates a normal immunological response. Microbiota imbalance has been involved in many disorders including cancers. There has been growing interest in the possible application of probiotics as a part of combination therapy with conventional treatment of cancer. As a result of recent years’ findings, probiotic bacteria have been gaining traction as a crucial component in successful cancer immunotherapy.

CRC is the third most common form of cancer. Diverse therapies such as chemotherapy, immunotherapy, and radiation have shown beneficial effects, but are limited because of their safety and toxicity. Research on CRC mice model treated by the probiotic mix composed of seven different strains of Lactobacilli, Bifidobacteria, and Streptococcus demonstrated suppression of CRC. Therefore, probiotics have shown great promise in CRC as preventive and early-stage therapeutics.

Helicobacter pylori which can disrupt the acid mucus barrier and colonize the gastric epithelium is found in patients who are suffering from gastric cancer, although over 80% of these patients are asymptomatic. Increased resistance to antibiotics and decreased compliance with the therapeutic regimens have led to the failure of eradication therapy. Probiotics, with direct and indirect inhibitory effects on H. pylori in both animal models and clinical trials, have recently been used as a supplementary treatment in H. pylori eradication therapy for the treatment of gastric cancer. Probiotics have been considered useful because of the improvements in H. pylori eradication rates and therapy-related side effects.

Liver cancer is the fifth most common cancer in men and the ninth in women and is the second most common cause of death from cancer worldwide. The gut microbiome has been related to the development of liver disorders such as liver cancer. It reported that probiotics inhibit hepatocellular carcinoma (HCC) progression in mice. Feeding a probiotics mixture to tumor-injected mice could shift the composition of gut microbiota and reduce the size of liver tumors. In addition to the reduction of tumor size, angiogenic factors were down-regulated by probiotics administration.

Changes in the vaginal microecological environment may result in multiple gynecological diseases, including cervical cancer. Cervical cancer is the third most commonly diagnosed cancer and the fourth leading cause of cancer-related deaths among women worldwide. Recent studies have shown that Lactobacillus may play an important role in the occurrence and development of cervical cancer.

NGPs Discovery Service at Creative Biolabs

Currently, it is widely accepted that most commercial probiotics are generally safe and can be used as a supplement for cancer prevention and treatment. Therefore, probiotics can be potentially used as an alternative therapy for cancer control. With our state-of-the-art technology and industry-leading expertise, Creative Biolabs performs probiotics identification for single strains and blends. Our comprehensive portfolio of microbial and stability testing analysis fully supports all the processes of GMP. Our seasoned scientists are experts at project evaluation through technical, economic, sustainability, and engineering to translate from lab scale to scale up.

If you need to boost your R&D capacities in the NGPs development for cancer prevention and treatment, we can help you to achieve your goals in time, maintaining quality and cost. For more detailed information, please feel free to contact us or directly send us an inquiry.

Reference

  1. Górska, A.; et al. Probiotic bacteria: a promising tool in cancer prevention and therapy. Current microbiology. 2019, 1:1-1.

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Live Biotherapeutics Drug Discovery

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Contact us

Contact us

Copyright © 2022 Creative Biolabs. All Rights Reserved.

Inquiry Basket